Opendata, web and dolomites

HEXKIN

Healing Exosomes for sKIN

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HEXKIN project word cloud

Explore the words cloud of the HEXKIN project. It provides you a very rough idea of what is the project "HEXKIN" about.

instrument    successful    capital    humans    70    standard    position    million    clinical    exo    biocompatibility    ucb    skin    reported    survival    considering    treatment    believe    close    human    generate    segment    care    revenues    market    assist    fast    cell    place    patients    wound    trials    solutions    cells    limited    maintaining    spin    validate    gap    opportunity    entrance    demand    company    vascularisation    valley    healing    swift    accomplishment    improvements    capacity    engraftment    efficacy    globally    burden    competition    tool    death    business    sme    ideal    nevertheless    promotion    clinically    active    therapeutic    global    commercialization    commercialisation    ulcers    therapies    currently    blood    reveal    diabetic    vehicle    competitive    constitute    hard    classic    wounds    strategies    accelerate    stimulation    emerged    overcome    secreted    heal    exogenus    models    animal    secure    suffering    healthcare    stages    chronic    severe    restricted    safety    validation    umbilical    cord   

Project "HEXKIN" data sheet

The following table provides information about the project.

Coordinator
EXOGENUS THERAPEUTICS SA 

Organization address
address: PARQUE BIOCANT NUCLEO 04 LOTE 2
city: CANTANHEDE
postcode: 3060 197
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Project website http://www.exogenus-t.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EXOGENUS THERAPEUTICS SA PT (CANTANHEDE) coordinator 50˙000.00

Map

 Project objective

Currently, there are about 50 million reported cases globally of patients suffering from hard-to-close wounds, which constitute a severe cost burden to the global healthcare systems. Considering that for these patients up to 70% of the wounds may not heal with standard care, there is a high demand for new solutions with better efficacy for the treatment of wounds. Cell therapies have emerged as promising therapeutic strategies to solve the problem of chronic wounds, but the limited engraftment and survival of the cells have restricted their efficacy in late stages of human trials. Exogenus is a spin-out company dedicated to develop a new therapeutic tool for the treatment of chronic wounds – Exo-Wound - which the company now seeks to clinically validate for diabetic ulcers. Exo-Wound is based on factors secreted by Umbilical Cord Blood (UCB) cells which accelerate the healing of skin wounds through promotion of vascularisation and stimulation of skin growth. Results from the animal models reveal important improvements in the healing capacity, treatment duration and biocompatibility when compared to competition. Nevertheless, in order to secure swift product development and successful commercialisation Exogenus is in need of partnerships and capital to overcome the classic ”Valley of death” gap. We believe the SME instrument is the ideal funding vehicle for us to establish Exo-Wound clinical validation and undertake the necessary activities to demonstrate safety and efficacy of the product in humans, and eventually achieve successful, global commercialization. The project will contribute to place Exogenus in a competitive position within the advanced wound care market and assist Europe in maintaining its competitive position in the fast growing segment of active therapies. The accomplishment of the project objectives will lead to a significant business opportunity for Exogenus, and generate revenues of around €30 million, five years after market entrance.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HEXKIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HEXKIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More